| scholarly article | Q13442814 |
| P50 | author | Marzia Del Re | Q42338594 |
| Romano Danesi | Q67479522 | ||
| Iacopo Petrini | Q39677318 | ||
| P2093 | author name string | Massimo Di Maio | |
| Stefano Fogli | |||
| Stefania Crucitta | |||
| Elena Arrigoni | |||
| Eleonora Rofi | |||
| Giuliana Restante | |||
| P2860 | cites work | Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors | Q40534298 |
| Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer | Q40591213 | ||
| EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient | Q40820004 | ||
| Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice | Q40827754 | ||
| PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. | Q40889616 | ||
| Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. | Q41015110 | ||
| Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown | Q41729089 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer | Q42382909 | ||
| Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report | Q43084814 | ||
| A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer | Q43098017 | ||
| A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer | Q43650682 | ||
| Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer | Q44425380 | ||
| Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777. | Q44435203 | ||
| Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions | Q44968631 | ||
| Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors | Q46137197 | ||
| Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial | Q46143489 | ||
| CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis | Q46492957 | ||
| Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma | Q46607603 | ||
| A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). | Q51629344 | ||
| Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non-Small Cell Lung Cancer | Q52985312 | ||
| Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer | Q53309223 | ||
| 2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC. | Q54174008 | ||
| Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS | Q56608513 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| KRAS oncogene in lung cancer: focus on molecularly driven clinical trials | Q26765353 | ||
| Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities | Q27345462 | ||
| A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations | Q27851664 | ||
| Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome | Q27851703 | ||
| A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response | Q27851728 | ||
| Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial | Q27851852 | ||
| Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 | ||
| Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer | Q27853180 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma | Q28115044 | ||
| KRAS mutations in non-small cell lung cancer | Q28240568 | ||
| Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene | Q28265475 | ||
| GEFs and GAPs: critical elements in the control of small G proteins | Q28304540 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Clonal evolution in cancer | Q29547696 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| The emerging mechanisms of isoform-specific PI3K signalling | Q29617954 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. | Q31982994 | ||
| A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer | Q33419105 | ||
| U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. | Q33829794 | ||
| Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer | Q33901988 | ||
| Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression | Q33956097 | ||
| RAS Interaction with PI3K: More Than Just Another Effector Pathway | Q34202692 | ||
| Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine | Q34217662 | ||
| The BATTLE trial: personalizing therapy for lung cancer | Q34275011 | ||
| FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements | Q34359341 | ||
| The history and future of targeting cyclin-dependent kinases in cancer therapy | Q34460347 | ||
| Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? | Q34577740 | ||
| Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib | Q34625305 | ||
| Histone deacetylase inhibitors in cancer therapy | Q34659283 | ||
| Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy | Q34701196 | ||
| The mutational landscapes of genetic and chemical models of Kras-driven lung cancer | Q35007114 | ||
| Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer | Q35123203 | ||
| Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial | Q35168763 | ||
| Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer | Q35256618 | ||
| EPMA position paper in cancer: current overview and future perspectives | Q35532215 | ||
| Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience | Q35541778 | ||
| PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients | Q35677709 | ||
| The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models | Q35835097 | ||
| The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells | Q35870933 | ||
| K-ras as a target for cancer therapy | Q36248002 | ||
| Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study | Q36284430 | ||
| Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models | Q36357215 | ||
| PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis | Q36378189 | ||
| Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. | Q36398758 | ||
| Mechanisms of immune evasion by tumors | Q36490750 | ||
| Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake? | Q36594244 | ||
| Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. | Q36716682 | ||
| Prognostic Significance of Aquaporin 5 Expression in Non-small Cell Lung Cancer | Q36719067 | ||
| Ras oncogenes and their downstream targets | Q36788722 | ||
| A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. | Q36865033 | ||
| Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases | Q36924440 | ||
| Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. | Q37000646 | ||
| PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations | Q37012531 | ||
| PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations | Q37013280 | ||
| Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). | Q37126929 | ||
| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade | Q37173548 | ||
| Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions | Q37209222 | ||
| The genetics and biology of KRAS in lung cancer | Q37354111 | ||
| ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer | Q37416902 | ||
| A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer | Q37417712 | ||
| Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC. | Q37702172 | ||
| Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. | Q37706672 | ||
| Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma | Q37708857 | ||
| Targeting MEK for the Treatment of Non–Small-Cell Lung Cancer | Q38060508 | ||
| KRAS mutations as prognostic and predictive markers in non-small cell lung cancer | Q38092565 | ||
| Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. | Q38288761 | ||
| FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. | Q38371186 | ||
| Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lun | Q38382765 | ||
| MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens | Q38383649 | ||
| A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer | Q38417869 | ||
| KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
| K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature | Q38742728 | ||
| Heat shock protein antagonists in early stage clinical trials for NSCLC. | Q38748687 | ||
| Giving AXL the axe: targeting AXL in human malignancy | Q38772267 | ||
| siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells | Q38822919 | ||
| Selumetinib in the treatment of non-small-cell lung cancer | Q38836927 | ||
| HSP90 inhibitors in lung cancer: promise still unfulfilled | Q38886469 | ||
| Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
| Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis | Q38983624 | ||
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
| KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies | Q39213209 | ||
| Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. | Q39248696 | ||
| Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling | Q39252593 | ||
| Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib | Q39271324 | ||
| Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. | Q39354188 | ||
| KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib | Q39602079 | ||
| GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition | Q39606314 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). | Q40125576 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma. | Q40402748 | ||
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. | Q40408396 | ||
| Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras | Q40434413 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6630-6643 | |
| P577 | publication date | 2017-12-21 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Implications of KRAS mutations in acquired resistance to treatment in NSCLC | |
| P478 | volume | 9 |
| Q102220308 | Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib |
| Q97538360 | Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer |
| Q91671471 | KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC |
| Q54109659 | Research Progress of KRAS Mutation in Non-small Cell Lung Cancer |
Search more.